Lack Evidence of Renal Impairment Complaints among Multiple Sclerosis Patients
DOI:
https://doi.org/10.61841/5h7qe853Keywords:
MS, Renal Impairment and Bladder ProblemsAbstract
Introduction: Multiple sclerosis MS is a demyelinated, inflammatory disease. Several researchers referred to the fact that the dysfunction in non-neural tissues plays a crucial role in MS disease pathogenesis. Patients and methods: 150 patients were included in this study. The demographic data has been obtained from all patients, as well as renal function, co-morbidities, and type of MS. Type of drug and bladder symptoms have been recorded. Results: Our results showed that the renal function test was followed (mean ± SD): serum creatinine 0.9 ± 1.6, blood urea 35.2 ± 15.7, and eGFR 111.4 ± 35.2. Co-morbidities: hypertension (20 patients) and diabetes (10 patients). Higher numbers of patients were diagnosed with RRMS (128 patients), and lower numbers were diagnosed with SPMS (5 patients). Most of the patients were using the interferon-beta drug (114 patients). Generally, 55 patients complained of bladder incontinence, 50 patients complained of retention, and 31 patients complained of recurrent UTIs. Conclusion: We revealed that renal impairment may not be associated with MS regarding our finding, but MS could be associated with bladder problems.
Downloads
References
[1] Rostami S, Emami-Aleagha M-S, Ghasemi-Kasman M, Allameh A. Cross-talks between the kidneys and the central nervous system in multiple sclerosis. Caspian Journal of Internal Medicine. 2018;9(3):206.
[2] Compston A, Winedl H, Kieseier B, Coles A. Multiple sclerosis. Lancet. 2002;359:1221-31.
[3] Compston A, Coles A. Multiple sclerosis. Lancet (Lond, Engl) 372: 1502–1517. 2008.
[4] Compston AC, Cole A. A. (2002). Multiple sclerosis. Lancet. 359:1221-31.
[5] Bertelson JA, Price BH. Depression and psychosis in neurological practice. Neurology in Clinical Practice:
Principles of diagnosis and management. 2004;1:103.
[6] Katsara M, Matsoukas J, Deraos G, Apostolopoulos V. Towards immunotherapeutic drugs and vaccines against multiple sclerosis. Acta biochimica et biophysica Sinica. 2008;40(7):636-42.
[7] Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996;46(4):907-11.
[8] Eckstein C, Bhatti MT. Currently approved and emerging oral therapies in multiple sclerosis: An update for
The ophthalmologist. Survey of ophthalmology. 2016;61(3):318-32.
[9] Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Annals of neurology. 2007;61(4):288-99.
[10] Ghasemi N, Razavi S, Nikzad E. Multiple sclerosis: pathogenesis, symptoms, diagnoses, and cell-based therapy. Cell Journal (Yakhteh). 2017;19(1):1.
[11] Sathyanesan M, Girgenti M, Banasr M, Stone K, Bruce C, Guilchicek E, et al. A molecular characterization of the choroid plexus and stress-induced gene regulation. Translational Psychiatry. 2012;2(7):e139-e.
[12] Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Harrison's principles of internal medicine: McGraw-Hill, New York; 2012.
[13] Ackley B. Ladwig, GB. Nursing diagnosis handbook: An evidence-based guide to planning care. 9th ed. St
Louis, MO: Mosby Elsevier. 2011.
[14] Calabresi P, Austin H, Racke M, Goodman A, Choyke P, Maloni H, et al. Impaired renal function in
progressive multiple sclerosis. Neurology. 2002;59(11):1799-801.
[15] Lawrenson R, Wyndaele J-J, Vlachonikolis I, Farmer C, Glickman S. Renal failure in patients with
neurogenic lower urinary tract dysfunction. Neuroepidemiology. 2001;20(2):138-43.
[16] Yuruktumen A, Karcioglu O, Topacoglu H, Arslan ED. Acute renal failure associated with dysfunctioning detrusor muscle in multiple sclerosis. Advances in therapy. 2004;21(6):343-7.
[17] Shakir NA, Satyanarayan A, Eastman J, Greenberg BM, Lemack GE. Assessment of renal deterioration and associated risk factors in patients with multiple sclerosis. Urology. 2019;123:76-80.
[18] Gonor SE, Carroll DJ, Metcalfe JB. Vesical dysfunction in multiple sclerosis. Urology. 1985;25(4):429-31.
[19] Betts CD, D'Mellow M, Fowler CJ. Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry. 1993;56(3):245-50.
[20] Gallien P, Robineau S, Nicolas B, Le Bot M-P, Brissot R, Verin M. Vesicourethral dysfunction and urodynamic findings in multiple sclerosis: a study of 149 cases. Archives of physical medicine and rehabilitation. 1998;79(3):255-7.
[21] Kasabian NG, Krause I, Brown WE, Khan Z, Nagler HM. Fate of the upper urinary tract in multiple sclerosis. Neurourology and Urodynamics. 1995;14(1):81-5.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 AUTHOR
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
